AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Argent BioPharma Limited

0.044

-0.006-12.00%

Volume:7.89K

Turnover:347.00

Market Cap:3.87M

PE:-0.36

High:0.044

Open:0.044

Low:0.044

Close:0.050

52wk High:0.320

52wk Low:0.044

Shares:87.94M

Float Shares:27.70M

Volume Ratio:0.10

T/O Rate:0.03%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.123

EPS(LYR):-0.312

ROE:--

ROA:-243.04%

PB:-0.46

PE(LYR):-0.14

Loading ...

Overview Company News Filings

Argent BioPharma H1 revenue jumps 39.0x to AUD 171,499

Argent Biopharma Files USPTO Provisional Patent for NanoBodies Platform Targeting Septic Shock

Argent Biopharma Delivers 1,000-Unit CannEpil Shipment to Ireland

Argent Biopharma Ltd-Streamlined Acquisition of Auscann Assets

THOMSON REUTERS

Argent Biopharma Ltd - to Buy Auscann's 48% Equity in Cannpal for a$2M

THOMSON REUTERS

Argent BioPharma Terminates CFO Igor Bluvstein

Argent Biopharma Ltd-Corporate Update

THOMSON REUTERS

Argent Biopharma Ltd - Transitions Financial Management to Australia

THOMSON REUTERS

Argent Biopharma Secures A$11m Financing Facility from C/M Capital for Strategic Acquisition

Argent Biopharma Announces Private Placement to Raise Capital

Argent Biopharma Ltd-Proposed Issue of Securities - RGT

THOMSON REUTERS

Argent Biopharma Ltd-a$11M Financing Facility to Complete Strategic Acquisition

THOMSON REUTERS

Argent Biopharma Ltd. Announces Date for Upcoming Annual General Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RGT.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RGT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RGT.AU\",,,,,undefined,":{"symbol":"RGT.AU","market":"AU","secType":"STK","nameCN":"Argent BioPharma Limited","latestPrice":0.044,"timestamp":1772687520000,"preClose":0.05,"halted":0,"volume":7886,"delay":0,"changeRate":-0.1200000000000001,"nameEN":"Argent BioPharma Limited","floatShares":27704074,"shares":87942317,"eps":-0.123189,"marketStatus":"Not Yet Opened","change":-0.006,"latestTime":"03-05 16:12:00 AEDT","open":0.044,"high":0.044,"low":0.044,"amount":347,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.123189,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1772751600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.05,"openAndCloseTimeList":[[1772665200000,1772686800000]],"volumeRatio":0.09659007393239426,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RGT.AU\",,,,,undefined,":{"symbol":"RGT.AU","floatShares":27704074,"roa":"-243.04%","roe":"--","lyrEps":-0.312116,"volumeRatio":0.09659007393239426,"shares":87942317,"dividePrice":0,"high":0.044,"amplitude":0,"preClose":0.05,"low":0.044,"week52Low":0.044,"pbRate":"-0.46","psRate":"11.13","week52High":0.32,"institutionHeld":0,"latestPrice":0.044,"eps":-0.123189,"divideRate":0,"volume":7886,"delay":0,"ttmEps":-0.123189,"open":0.044,"prevYearClose":0.07,"prevWeekClose":0.056,"prevMonthClose":0.056,"prevQuarterClose":0.07,"fiveDayClose":0.056,"twentyDayClose":0.054,"sixtyDayClose":0.073},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RGT.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-09-23","symbol":"RGT.AU","reason":null,"defaultRemindTime":1727049600000,"announcedDate":"2024-08-15","type":"delisting","dateTimestamp":1727013600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RGT.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RGT.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614884316","title":"Argent BioPharma H1 revenue jumps 39.0x to AUD 171,499","url":"https://stock-news.laohu8.com/highlight/detail?id=2614884316","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614884316?lang=en_us&edition=fundamental","pubTime":"2026-02-27 15:20","pubTimestamp":1772176848,"startTime":"0","endTime":"0","summary":"Argent BioPharma reported revenue from ordinary activities of AUD 171,499 for H1 ended 31 December 2025, a 39.0x increase, and a net loss attributable to members of AUD 2.9 million . Net tangible assets per share were (0.1) cents at 31 December 2025. Cash and cash equivalents were AUD 1.5 million at 31 December 2025, while net cash used in operating activities was AUD 2.6 million for H1. During the period, Argent BioPharma began formal supply of EU-GMP cannabinoid API to University Medical Centre Ljubljana for drug-resistant epilepsy, and published a peer-reviewed CannEpil case study in treatment-resistant epilepsy. The company also cited an independent in vivo study by the University of South Florida showing up to 85% survival in treated mice for ArtemiC in a viral inflammatory model. In December 2025, the group liquidated its Slovenian subsidiary following a decision to cease operations at its Slovenia manufacturing facility, recording a AUD 55,395 loss on liquidation. Subsequent to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL9BBpN2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Argent BioPharma H1 revenue jumps 39.0x to AUD 171,499","news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2614575729","title":"Argent Biopharma Files USPTO Provisional Patent for NanoBodies Platform Targeting Septic Shock","url":"https://stock-news.laohu8.com/highlight/detail?id=2614575729","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614575729?lang=en_us&edition=fundamental","pubTime":"2026-02-25 06:42","pubTimestamp":1771972943,"startTime":"0","endTime":"0","summary":"Argent BioPharma Ltd. said it has filed a U.S. provisional patent application with the USPTO for its NanoBodies platform , covering designated peptide targets and related nanobody constructs aimed at septic shock and systemic inflammation. The company said the filing establishes a 12-month priority period to further develop and support the intellectual property.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. published the original content used to generate this news brief on February 25, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL7k2r5C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2613274239","title":"Argent Biopharma Delivers 1,000-Unit CannEpil Shipment to Ireland","url":"https://stock-news.laohu8.com/highlight/detail?id=2613274239","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613274239?lang=en_us&edition=fundamental","pubTime":"2026-02-23 07:02","pubTimestamp":1771801340,"startTime":"0","endTime":"0","summary":"Argent BioPharma Ltd. said 1,000 units of its CannEpil product arrived in Ireland in what it described as its largest single commercial shipment to date. The company said the shipment has an approximate reimbursed retail value of about A$783,000 and will be distributed by its Irish commercial partner Georgelle Pharma in collaboration with logistics partner Versa Pharmaceuticals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. published the original content used to generate this news brief on February 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260222:nNDL3hkK6P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2603655322","title":"Argent Biopharma Ltd-Streamlined Acquisition of Auscann Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2603655322","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603655322?lang=en_us&edition=fundamental","pubTime":"2026-01-14 06:26","pubTimestamp":1768343168,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUE8CXH1V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RGT.AU"],"gpt_icon":0},{"id":"2603553276","title":"Argent Biopharma Ltd - to Buy Auscann's 48% Equity in Cannpal for a$2M","url":"https://stock-news.laohu8.com/highlight/detail?id=2603553276","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603553276?lang=en_us&edition=fundamental","pubTime":"2026-01-14 06:26","pubTimestamp":1768343168,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUE8CXH1V:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RGT.AU"],"gpt_icon":0},{"id":"2589069288","title":"Argent BioPharma Terminates CFO Igor Bluvstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2589069288","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589069288?lang=en_us&edition=fundamental","pubTime":"2025-12-08 05:36","pubTimestamp":1765143389,"startTime":"0","endTime":"0","summary":"Argent BioPharma Ltd. has terminated the employment agreement of Mr Igor Bluvstein, who served as Chief Financial Officer, and removed him from all positions within the company's subsidiaries effective immediately. The company is restructuring its finance and reporting functions, transitioning all financial management activities from its internal team in Slovenia to an external provider in Australia.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. published the original content used to generate this news brief on December 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL88ts8C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2589986806","title":"Argent Biopharma Ltd-Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2589986806","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589986806?lang=en_us&edition=fundamental","pubTime":"2025-12-08 05:30","pubTimestamp":1765143007,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nTUE2TYVQ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2589069828","title":"Argent Biopharma Ltd - Transitions Financial Management to Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2589069828","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589069828?lang=en_us&edition=fundamental","pubTime":"2025-12-08 05:30","pubTimestamp":1765143007,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nTUE2TYVQ1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RGT.AU"],"gpt_icon":0},{"id":"2584699456","title":"Argent Biopharma Secures A$11m Financing Facility from C/M Capital for Strategic Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2584699456","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584699456?lang=en_us&edition=fundamental","pubTime":"2025-11-17 07:03","pubTimestamp":1763334212,"startTime":"0","endTime":"0","summary":"Argent Biopharma Ltd. has secured a new A$11 million financing facility with US-based venture fund C/M Capital to support the completion of its strategic acquisition of AusCann Group assets and to finance future growth strategies. The agreement, involving two institutional funds managed by C/M Capital Partners, LP, provides an immediate A$3 million drawdown for working capital and the acquisition. Additionally, Argent has executed a deed of variation with Mercer Street Global Fund LLC to amend the terms of existing convertible notes, subject to shareholder approval at the 2025 Annual General Meeting. This funding positions Argent to complete its acquisition, strengthen its operational and financial base, and accelerate its plans for a dual listing on a major US stock exchange.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for information","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251116:nNDLccn5L4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RGT.AU"],"gpt_icon":0},{"id":"2584994596","title":"Argent Biopharma Announces Private Placement to Raise Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584994596","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584994596?lang=en_us&edition=fundamental","pubTime":"2025-11-17 07:03","pubTimestamp":1763334205,"startTime":"0","endTime":"0","summary":"Argent Biopharma Ltd. has announced a proposed placement involving the issue of 21,950,952 unlisted options and 11,000,000 convertible notes. The placement is subject to security holder approval, with the determination set for November 28, 2025. The funds raised through this offering are intended to support the completion of the AusCann transaction and provide general working capital for operational activities. The proposed issue date for the securities is December 1, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251116:nNDL97dc8q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2584699529","title":"Argent Biopharma Ltd-Proposed Issue of Securities - RGT","url":"https://stock-news.laohu8.com/highlight/detail?id=2584699529","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584699529?lang=en_us&edition=fundamental","pubTime":"2025-11-17 06:44","pubTimestamp":1763333074,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251116:nTUE8FGLBT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2584544699","title":"Argent Biopharma Ltd-a$11M Financing Facility to Complete Strategic Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2584544699","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584544699?lang=en_us&edition=fundamental","pubTime":"2025-11-17 06:42","pubTimestamp":1763332945,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251116:nTUE4ZT0MM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2579927840","title":"Argent Biopharma Ltd. Announces Date for Upcoming Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2579927840","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579927840?lang=en_us&edition=fundamental","pubTime":"2025-10-29 16:50","pubTimestamp":1761727824,"startTime":"0","endTime":"0","summary":"Argent Biopharma Ltd. will hold its Annual General Meeting on 28 November 2025 at Suite 1, 295 Rokeby Road, Subiaco, WA. Shareholders will receive and consider the company's annual financial report for the year ended 30 June 2025, including the Directors' declaration, the Directors' report, the Remuneration Report, and the auditor's report. Resolutions to be voted on during the meeting include the adoption of the Remuneration Report, the election of Director Gary Hermon, approval for the company to issue up to 10% of its issued capital under a 7.1A mandate, and the renewal of proportional takeover provisions in the company's constitution for a further three years.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. pub","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL8gsfY8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGT.AU","BK7096"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}]}}